Teladoc Health, Inc.(TDOC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,088 of 2,960 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
TDOC Stock Analysis & AI Quality Score
Data updated 2026-09-10AI stock analysis and institutional research for Teladoc Health, Inc. (TDOC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TDOC at 40.8/100 on a 32-signal composite quality model, placing it at rank #2,088 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (18.5) and balance sheet strength (20.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 31.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Teladoc Health, Inc. reports quarterly revenue of $606.9M, net income of $-38.9M, an operating margin of -6.1%. Top institutional holders of TDOC by reported 13-F value include TENOR CAPITAL MANAGEMENT , L.P., D. E. Shaw, BlackRock, based on the most recent SEC filings. TDOC trades on the NYSE exchange and files with the SEC under CIK 1477449. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TDOC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Teladoc Health, Inc. directly from SEC EDGAR. Teladoc Health, Inc.'s 13F Pro composite quality score has ranged between 36 and 51 since 2022, currently 40.8 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$606.9M
Net Income
Q2 2026
$-38.9M
Free Cash Flow
Q2 2026
$63.7M
Operating Margin
Q2 2026
-6.1%
ROIC
Q2 2026
-11.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-1.5% YoYNet Income
+80.0% YoYOperating Income
+74.2% YoYEPS (Diluted)
+80.6% YoYTotal Assets
-18.7% YoYTotal Debt
Op. Cash Flow
+0.2% YoYFree Cash Flow
+0.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.53B -1.5% | $2.57B -1.3% | $2.60B +8.1% | $2.41B +18.4% | $2.03B +85.8% | $1.09B |
| Net Income | $-200.3M +80.0% | $-1.00B -354.4% | $-220.4M +98.4% | $-13.66B -3085.6% | $-428.8M +11.6% | $-485.1M |
| Operating Income | $-263.0M +74.2% | $-1.02B -310.7% | $-248.6M +98.2% | $-13.65B -5039.9% | $-265.6M +47.5% | $-506.4M |
| EPS (Diluted) | $-1.14 +80.6% | $-5.87 -338.1% | $-1.34 +98.4% | $-84.60 -2998.9% | $-2.73 +49.1% | $-5.36 |
| Total Assets | $2.86B -18.7% | $3.52B -19.9% | $4.39B +1.1% | $4.35B -75.5% | $17.73B -0.1% | $17.76B |
| Total Debt | — | — | — | — | $0.00 -100.0% | $42.6M |
| Operating Cash Flow | $294.4M +0.2% | $293.7M -16.1% | $350.0M +84.9% | $189.3M -2.4% | $194.0M +462.5% | $-53.5M |
| Free Cash Flow | $285.5M +0.9% | $282.9M -16.4% | $338.6M +95.9% | $172.8M -6.8% | $185.5M +422.3% | $-57.5M |
Get alerted when TDOC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Teladoc Health, Inc. including:
Top Institutional Holders of TDOC
TENOR CAPITAL MANAGEMENT Co., L.P.
$181.3M186,000,000 shD. E. Shaw & Co., Inc.
$146.1M149,917,000 shBlackRock, Inc.
$137.6M16,223,134 shVANGUARD PORTFOLIO MANAGEMENT LLC
$107.6M12,685,592 shContext Capital Management, LLC
$102.8M105,459,000 shARISTEIA CAPITAL, L.L.C.
$75.4M77,338,000 shDeepCurrents Investment Group LLC
$71.0M73,000,000 shPoint72 Asset Management, L.P.
$69.9M8,239,927 shRENAISSANCE TECHNOLOGIES LLC
$68.5M8,072,842 shVoss Capital, LP
$68.2M8,046,679 sh
| Fund | Value | Shares |
|---|---|---|
| TENOR CAPITAL MANAGEMENT Co., L.P. | $181.3M | 186,000,000 |
| D. E. Shaw & Co., Inc. | $146.1M | 149,917,000 |
| BlackRock, Inc. | $137.6M | 16,223,134 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $107.6M | 12,685,592 |
| Context Capital Management, LLC | $102.8M | 105,459,000 |
| ARISTEIA CAPITAL, L.L.C. | $75.4M | 77,338,000 |
| DeepCurrents Investment Group LLC | $71.0M | 73,000,000 |
| Point72 Asset Management, L.P. | $69.9M | 8,239,927 |
| RENAISSANCE TECHNOLOGIES LLC | $68.5M | 8,072,842 |
| Voss Capital, LP | $68.2M | 8,046,679 |
Companies Similar to TDOC
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Sarepta Therapeutics, Inc.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Fortrea Holdings Inc.
Enovis CORP
Elanco Animal Health Inc
Viatris Inc
NOVAVAX INC
Emergent BioSolutions Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put TDOC on your watchlist
Track score changes the day Teladoc Health, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TDOC a good stock to buy?
13F Pro's AI-powered analysis of Teladoc Health, Inc. (TDOC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TDOC are available on the TDOC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TDOC is classified as a small company.
Which hedge funds own TDOC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TDOC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Teladoc Health, Inc.'s investment landscape.